Bupropion SR for relapse prevention: a "slips-allowed" analysis.
OBJECTIVE
To assess the efficacy of bupropion SR on smoking abstinence using a "slips allowed" analysis.


METHODS
Retrospective analysis, which did not consider brief episodic "slips" as a return to regular smoking, of data from a multicenter, randomized, doubleblind, placebo-controlled relapse prevention study.


RESULTS
Using a slips-allowed analysis, median time to relapse on bupropion SR was 65 weeks versus 30 weeks on placebo. This is compared to 32 and 20 weeks, respectively, using a traditional analysis not allowing for slips.


CONCLUSIONS
Bupropion SR is efficacious for the prevention of smoking relapse. A slips-allowed analysis may provide a more clinically relevant assessment of efficacy.
Smoking Control, GlaxoSmithKline, 1500 Littleton Road, Parsippany, NJ 07054, USA. Michael.J.Durcan@GSK.com
Michael J
MJ
Durcan
J Andrew
JA
Johnston
Jonathan
J
White
David
D
Gonzales
David P L
DP
Sachs
Nancy
N
Rigotti
Raymond
R
Niaura
D000293:Adolescent; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D016642:Bupropion / Q000627:therapeutic use*; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D055502:Secondary Prevention; D012907:Smoking / Q000453:epidemiology*; D016540:Smoking Cessation / Q000379:methods*; D000074606:Smoking Prevention; D011795:Surveys and Questionnaires
D018687:Antidepressive Agents, Second-Generation; D003692:Delayed-Action Preparations; D016642:Bupropion